Synchron

Synchron is pioneering a minimally invasive brain-computer interface platform that aims to restore autonomy to people with severe paralysis. Its flagship technology, the Stentrode, is implanted via blood vessels, offering a safer alternative to open-brain surgery BCIs. The company is actively conducting clinical trials in the US and Australia and has secured significant funding and a Breakthrough Device designation from the FDA. Synchron is positioned as a leading contender in the emerging neurotechnology market, competing to bring the first commercially viable BCI to patients.

Endovascular brain-computer interface (BCI) featuring the Stentrode, a stent-like electrode array implanted via blood vessels to record neural signals for wireless control of digital devices.

Synchron competes in the emerging BCI field against companies like Neuralink (invasive cortical implants) and Paradromics (high-density surface arrays). Its primary competitive differentiation is its minimally invasive endovascular approach, which offers potential safety and surgical scalability advantages over open-brain surgery methods, though it may trade off some signal resolution.